Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Immatics ( (IMTX) ).
On January 12, 2026, Immatics N.V. filed a report with U.S. securities regulators announcing that it had posted an updated corporate investor presentation on its website, formally placing the materials in the public domain. The presentation highlights the company’s expanding pipeline of PRAME‑targeted product candidates, including the TCR‑T cell therapy anzutresgene autoleucel (anzu‑cel, formerly IMA203), its second‑generation IMA203CD8, and the bispecific antibody IMA402, which are being advanced across multiple solid tumor indications and stages of development from Phase 1 through preclinical. By emphasizing its leadership in precision PRAME targeting and outlining a multi‑modality development strategy in melanoma, gynecologic cancers and other solid tumors, Immatics is signaling to investors and partners its intent to consolidate a competitive position in next‑generation cancer immunotherapy, although the company stresses that the information is current only as of the presentation date and may be subject to future change.
The most recent analyst rating on (IMTX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.
Spark’s Take on IMTX Stock
According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.
Immatics’ overall stock score is primarily influenced by its financial performance challenges, including inconsistent revenue growth and profitability. Positive technical indicators provide some support, suggesting potential short-term bullish momentum. However, the negative P/E ratio and lack of dividend yield highlight valuation concerns. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on IMTX stock, click here.
More about Immatics
Immatics N.V., based in Tübingen, Germany, operates in the biotechnology sector with a focus on cancer immunotherapies that precisely target intracellular tumor antigens presented by HLA molecules. The company is positioning itself as a global leader in targeting the PRAME antigen across a broad range of solid tumors, developing both engineered T‑cell receptor (TCR) cell therapies and TCR‑based bispecifics aimed at indications such as melanoma, gynecologic cancers and non‑small cell lung cancer.
Average Trading Volume: 605,014
Technical Sentiment Signal: Buy
Current Market Cap: $1.25B
See more data about IMTX stock on TipRanks’ Stock Analysis page.